The most significant reasons for the failure of treatment of patients with newly diagnosed pulmonary tuberculosis and possible solutions

DOI: https://doi.org/10.32902/2663-0338-2020-3-35-42

Abstract

ABSTRACT. The paper summarizes the results of studies regarding the most significant causes of ineffective treatment of patients with newly diagnosed pulmonary tuberculosis. It is proven that the effectiveness of treatment depends from the maximum concentration of antituberculosis drugs in blood serum, tissues and foci of affected lungs, depending on the method of administration of drugs and the presence of concomitant pathology from hepatobiliary and gastrointestinal system tract. Recommendations are given regarding the prevention of ineffective treatment of patients with pulmonary tuberculosis by improving diagnosis and developing new treatment regimens.

Keywords: tuberculosis, effectiveness of treatment, concentration of drugs.

References

Feshchenko Y.I. et al. Assessment of tuberculosis control in Ukraine for period 2006-2010. Ukrainian Pulmonology Journal. 2011; 4: 5-10.

Mitnick C., McGee B., Peloquin C. Tuberculosis pharmacotherapy: strategies to optimize patient care. Expert Opin. Pharmacother. 2009; vol. 10, no. 3: 381-401.

Egorov A.M., Sazykin Y.O. Some problems of chemotherapy for tuberculosis, taking into account new data on its causative agent. Antibiotics and Chemotherapy. 2000; 5: 11-15.

March F. et al. Molecular genetics of drug resistant Mycobacterium tuberculosis. Intern. J. Tubercul. Lung Dis. 1997; vol. 25: 1044-1047.

Somoskovi А. et al. The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis. Intern. J. Tubercul. Lung Dis. 1998; vol. 2, no. 1: 72-89.

Sensi P. History of the development of rifampin. Clin. Infect. Dis. 1983; vol. 5, no. 3: 402-406.

Merle A. The use of rifampin in the treatment of nontuberculous infections. Reviews of Infectious Diseases. 1983; vol. 5, no. 3: 402-406.

Rattan A., Kalia A., Ahmad N. Multidrug-resistant Mycobacterium tuberculosis: molecular perspectives. Emerg. Infec. Dis. 1998; 4 (2): 195-209.

Egorov A.M., Sazykin Y.O. Chemotherapy of tuberculosis. On traditional and new approaches to the creation of antimycobacterial drugs. Antibiotics and Chemotherapy. 2002; 6: 3-6.

Starke J.R. Resurgence of tuberculosis in children. Pediatr. Pulmonol. 1997; 16: 154-156.

Mishin Y.V. Optimization of treatment of newly diagnosed pulmonary tuberculosis patients based on the principles of evidence-based medicine. Consilium Medicum Ukraina. 2010; 1 (4): 26-31.

Korovkin V.S. Antibacterial therapy of pulmonary tuberculosis. Available at: antibakterialnaja_terapija_UBERK_LEGKIH.doc.

Belousov Y.B. Clinical pharmacology and pharmacotherapy. – Moscow: MIA, 2010. – 872 с.

Kuzhko M.M. et al. Preclinical aspects of rifampicins in tuberculosis. Ukrainian Pulmonology Journal. 2012; 3: 104-107.

Kislitsyna N.A., Kotova N.I. Kontsentratsii rifampitsina v patologicheskikh obrazovaniiakh rezetsirovannykh legkikh [Concentration of rifampicin in pathological formations of resected lungs]. Probl. Tuberk. 1975; 6: 79-81.

Kislitsyna N.A. Sravnitel’naia otsenka proniknoveniia rifampitsina i izoniazida v patologicheskie ochagi legkikh bol’nykh tuberkulezom [Comparative evaluation of rifampicin and isoniazid penetration into the pathological foci of the lungs in tuberculosis patients]. Probl. Tuberk. 1985; 4: 55-57.

Ivanyuta O.M., Otroshchenko P.G. et al. Concentration of tuberculostatic drugs in the blood and lung tissue with various routes of administration. Probl. Tuberk. 1980; 8: 60-63.

Kislicina N.A., Kotova N.I. Concentration of rifampicin and isoniazid in the blood and resected lungs of tuberculosis patients with combined use of drugs. Probl. Tuberk. 1980; 8: 63-65.

Feshchenko Y. et al. Effectiveness of intravenous isoniazid and ethambutol administration in patients with tuberculosis meningoencephalitis and HIV infection. Tuberculosis and Respiratory Diseases. 2020; 83 (1): 96-103.

Feshchenko Y. et al. Efficacy and safety of intravenous chemotherapy during intensive treatment phase in patients with newly diagnosed pulmonary tuberculosis. Advances in Respiratory Medicine. 2018; vol. 86, no. 4: 159-167.

Published
2020-10-10
How to Cite
Kuzhko, M., Tlustova, T., Butov, D., Gumeniuk, M., Protsyk, L., & Taranenko, A. (2020). The most significant reasons for the failure of treatment of patients with newly diagnosed pulmonary tuberculosis and possible solutions. Infusion & Chemotherapy, (3), 35-42. https://doi.org/10.32902/2663-0338-2020-3-35-42
Issue
No. 3 (2020): INFUSION & CHEMOTHERAPY
Section
ORIGINAL STUDIES

Author Biographies

M.M. Kuzhko, National Institute of Phthisiology and Pulmonology named after F.G. Yanovsky NAMS of Ukraine, Kyiv

Kuzhko Mykhailo Mykhailovych
Leading researcher of Department of chemo-resistant tuberculosis
MD, professor.
10, M. Amosova st., Kyiv, 03038, Ukraine.

T.V. Tlustova, National Institute of Phthisiology and Pulmonology named after F.G. Yanovsky NAMS of Ukraine, Kyiv

Tlustova Tetiana Volodymyrivna
Head of the Department of Diagnostic of Chemically Resistant Forms of Tuberculosis
PhD.
10, Amosova st., Kyiv, 03038, Ukraine.

D.O. Butov, Kharkiv National Medical University, Kharkiv, Ukraine

Butov Dmytro Oleksandrovych
Associate Professor, Department of Phthisiology and Pulmonology
MD.
4, Science ave., Kharkiv, 61022, Ukraine.

M.I. Gumeniuk, National Institute of Phthisiology and Pulmonology named after F.G. Yanovsky NAMS of Ukraine, Kyiv

Gumeniuk Mykola Ivanovych
Leading Researcher, Department of Technologies of Treatment of Nonspecific Lung Diseases
MD.
10, M. Amosova st., Kyiv, 03038, Ukraine.

L.M. Protsyk, National Institute of Phthisiology and Pulmonology named after F.G. Yanovsky NAMS of Ukraine, Kyiv

Protsyk Liubomyr Myronovych
Senior Researcher
PhD.
10, M. Amosova st., Kyiv, 03038, Ukraine.

A.V. Taranenko, National Institute of Phthisiology and Pulmonology named after F.G. Yanovsky NAMS of Ukraine, Kyiv

Taranenko Andrii Volodymyrovych
10, M. Amosova st., Kyiv, 03038, Ukraine.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.